Condition: Biliary Tract Cancer · Sponsor: InnoPharmax Inc.
The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).
This description comes directly from the study's public registry record.
Yuyuan Lin · 886-87977607 · yuan.lin@innopharmax.com
Always discuss trial participation with your own doctor first.
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| National Taiwan University Cancer Center | Taipei, Taiwan | Recruiting |
| National Taiwan University Hospotal | Taipei, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05065957